Effectiveness and Adverse Events of Cyclophosphamide, Vincristine, and Prednisolone Chemotherapy in Feline Mediastinal Lymphoma Naturally Infected with Feline Leukemia Virus.
COP chemotherapy
adverse events
cat
feline leukemia virus
lymphoma
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
31 Mar 2022
31 Mar 2022
Historique:
received:
23
02
2022
revised:
25
03
2022
accepted:
28
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Feline leukemia virus (FeLV) infection is considered a poor prognostic factor for feline lymphoma. This study investigated the prevalence of cats suffering from feline lymphoma with natural infection of the feline leukemia virus, as well as clinical signs, adverse events, and survival time after cyclophosphamide, vincristine and prednisolone (COP) chemotherapy. This retrospective study involved 92 cats diagnosed with mediastinal or mediastinal plus other anatomical sites of lymphoma and treated with COP chemotherapy. FeLV-antigen-positive was observed in all cats. Clinical signs and adverse events were observed after the 1st, 2nd, and 3rd inductions. Clinical signs improved after the 3rd induction of COP chemotherapy. The response rate was 96.74% (81.52% complete response, 15.22% partial response, and 3.26% no response). The overall median survival time was 338 days (range 62−1057 days). The overall response rate and median survival time of cats with feline lymphoma that were FeLV-antigen-positive and treated with COP chemotherapy were higher than from other studies. This study found that cats aged <4 years survived longer than those aged at least 4 years. Anemia (before COP), azotemia (after 2nd induction), and elevated alanine aminotransferase (after 1st induction) were associated with an increased chance of mortality.
Identifiants
pubmed: 35405890
pii: ani12070900
doi: 10.3390/ani12070900
pmc: PMC8997098
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
Références
Vet Immunol Immunopathol. 2008 May 15;123(1-2):138-43
pubmed: 18313764
J Comp Pathol. 2019 Jan;166:20-28
pubmed: 30691602
J Vet Intern Med. 1994 Mar-Apr;8(2):99-104
pubmed: 8046683
J Vet Intern Med. 2002 Mar-Apr;16(2):179-86
pubmed: 11899035
J Vet Diagn Invest. 2000 Jul;12(4):295-306
pubmed: 10907857
J Feline Med Surg. 2018 Oct;20(10):934-939
pubmed: 29065803
Arch Virol. 1997;142(2):323-32
pubmed: 9125046
J Feline Med Surg. 2000 Jun;2(2):95-100
pubmed: 11716600
J Natl Cancer Inst. 1983 May;70(5):971-7
pubmed: 6573542
J Am Vet Med Assoc. 1989 Mar 1;194(5):696-702
pubmed: 2925488
J Feline Med Surg. 2019 Dec;21(12):1102-1110
pubmed: 30554552
Arch Virol. 2018 Apr;163(4):1073-1077
pubmed: 29353423
Vet Comp Oncol. 2021 Jun;19(2):311-352
pubmed: 33427378
J Vet Intern Med. 2008 Mar-Apr;22(2):394-400
pubmed: 18312554
J Vet Intern Med. 1998 Sep-Oct;12(5):349-54
pubmed: 9773411
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Vet Comp Oncol. 2016 Aug;14 Suppl 1:136-46
pubmed: 26109275
J Vet Intern Med. 2005 May-Jun;19(3):329-35
pubmed: 15954547
J Virol. 1994 Dec;68(12):8296-303
pubmed: 7966623
J Feline Med Surg. 2021 Feb;23(2):86-97
pubmed: 32684120
Vet Med Sci. 2015 Oct 29;1(2):51-62
pubmed: 29067174
J Vet Med Sci. 2014 Jun;76(6):807-11
pubmed: 24521793
Vet Comp Oncol. 2018 Mar;16(1):159-166
pubmed: 28556532
Aust Vet J. 1997 Jun;75(6):424-7
pubmed: 9247693
Animals (Basel). 2022 Jan 18;12(3):
pubmed: 35158547
Vet J. 2019 Mar;245:70-76
pubmed: 30819429
Aust Vet J. 1998 Nov;76(11):725-32
pubmed: 9862061
J Feline Med Surg. 2020 Jan;22(1):5-30
pubmed: 31916872
J Feline Med Surg. 2014 Aug;16(8):637-44
pubmed: 24366846
J Small Anim Pract. 2021 Feb;62(2):97-106
pubmed: 33325082
Vet Clin North Am Small Anim Pract. 2020 Sep;50(5):1013-1036
pubmed: 32680664
Med Sci (Basel). 2021 Jan 30;9(1):
pubmed: 33573146